Tumour-induced osteomalacia: A literature review and a case report

World Journal of Surgical Oncology

Volumn 14, Issue 1, 2016, Pages

  Dadoniene, Jolanta ^a,b   Miglinas, Marius ^a   Miltiniene, Dalia ^a,b   Vajauskas, Donatas ^a   Seinin, Dmitrij ^c   Butenas, Petras ^a   Kacergius, Tomas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

^b State Research Institute Centre for Innovative Medicine   (Lithuania)

^c National Centre of Pathology   (Lithuania)

Author keywords

Fibroblast growth factor 23; Hypophosphataemia; Tumour induced osteomalacia

Indexed keywords

ALKALINE PHOSPHATASE; FIBROBLAST GROWTH FACTOR 23; MEDRONATE TECHNETIUM TC 99M; PHOSPHORUS; RISEDRONIC ACID; SOMATOSTATIN RECEPTOR; VIMENTIN; ZOLEDRONIC ACID;

ADULT; ATELECTASIS; AUTOIMMUNE THYROIDITIS; BONE PAIN; BONE SCINTISCANNING; CASE REPORT; COMPRESSION FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILY HISTORY; FEMUR HEAD NECROSIS; HIP ARTHROPLASTY; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; KYPHOSIS; MALE; MIDDLE AGED; MULTIPLE FRACTURE; MUSCLE WEAKNESS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; OSTEOPENIA; PHOSPHATURIA; REVIEW; SCOLIOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE RADIOGRAPHY; STRESS FRACTURE; TUMOR LOCALIZATION; WEIGHT REDUCTION; WHOLE BODY SCINTISCANNING; COMPLICATION; FEMORAL NEOPLASMS; HEMANGIOPERICYTOMA; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES;

FEMORAL NEOPLASMS; HEMANGIOPERICYTOMA; HUMANS; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; OSTEOMALACIA; PARANEOPLASTIC SYNDROMES;

EID: 84953449430     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0763-7     Document Type: Review

References (61)

1. Deep NL, Cain RB, McCullough AE, Hoxworth JM, Lal D. Sinonasal phosphaturic mesenchymal tumor: case report and systematic review. Allergy Rhinol Provid RI. 2014;5(3):162-7.
2. Hamnvik O-PR, Becker CB, Levy BD, Loscalzo J. Clinical problem-solving. Wasting away N Engl J Med. 2014;370(10):959-66.
3. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30.
4. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36(1):104-5.
5. Ledford CK, Zelenski NA, Cardona DM, Brigman BE, Eward WC. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop. 2013;471(11):3618-25.
6. Sun Z, Jin J, Qiu G, Gao P, Liu Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord. 2015;16:43.
7. McCANCE RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.
8. Casari S, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni S, et al. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol. 2003;21(4):493-6.
9. Clunie GP, Fox PE, Stamp TC. Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatol Oxf Engl. 2000;39(12):1415-21.
10. Dowman JK, Khattak FH. Oncogenic hypophosphataemic osteomalacia mimicking bone metastases on isotope bone scan. Ann Rheum Dis. 2006;65(12):1664.
11. Fuentealba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N, et al. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2003;9(6):373-9.
12. Harbeck B, Schöcklmann H, Seekamp A, Czech N, Mönig H. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2009;15(1):31-4.
13. Wang H, Zhong D, Liu Y, Jiang Y, Qiu G, Weng X, et al. Surgical treatments of tumor-induced osteomalacia lesions in long bones: seventeen cases with more than one year of follow-up. J Bone Joint Surg Am. 2015;97(13):1084-94.
14. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med. 2007;357(4):422-4.
15. Prader A, Illig R, Uehlinger E, Stalder G. Rickets following bone tumor. Helv Paediatr Acta. 1959;14:554-65.
16. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53-77.
17. Meyer RA, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 1989;4(4):493-500.
18. Nesbitt T, Coffman TM, Griffiths R, Drezner MK. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest. 1992;89(5):1453-9.
19. Miyauchi A, Fukase M, Tsutsumi M, Fujita T. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. J Clin Endocrinol Metab. 1988;67(1):46-53.
20. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345-8.
21. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86(2):497-500.
22. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294(10):1260-7.
23. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006;27(3):221-41.
24. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab. 2012;30(1):1-9.
25. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19(3):429-35.
26. Ramon I, Kleynen P, Body J-J, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol Eur Fed Endocr Soc. 2010;162(1):1-10.
27. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol JASN. 2007;18(6):1637-47.
28. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500-5.
29. Hannan FM, Athanasou NA, Teh J, Gibbons CLMH, Shine B, Thakker RV. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol Eur Fed Endocr Soc. 2008;158(2):265-71.
30. Hu F-K, Yuan F, Jiang C-Y, Lv D-W, Mao B-B, Zhang Q, et al. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature. Chin J Cancer. 2011;30(11):794-804.
31. Weidner N. Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol. 1991;15(4-5):317-33.
32. Leaf DE, Pereira RC, Bazari H, Jüppner H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab. 2013;98(3):887-91.
33. Duet M, Kerkeni S, Sfar R, Bazille C, Lioté F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33(11):752-6.
34. Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy-clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95(10):4511-7.
35. Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711-8.
36. Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001;30(2):99-103.
37. Jiang Y, Xia W, Xing X, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res Off J Am Soc Bone Miner Res. 2012;27(9):1967-75.
38. Gardner KH, Shon W, Folpe AL, Wieland CN, Tebben PJ, Baum CL. Tumor-induced osteomalacia resulting from primary cutaneous phosphaturic mesenchymal tumor: a case and review of the medical literature. J Cutan Pathol. 2013;40(9):780-4. quiz 779.
39. Seijas R, Ares O, Sierra J, Pérez-Dominguez M. Oncogenic osteomalacia: two case reports with surprisingly different outcomes. Arch Orthop Trauma Surg. 2009;129(4):533-9.
40. Lewiecki EM, Urig EJ, Williams RC. Tumor-induced osteomalacia: lessons learned. Arthritis Rheum. 2008;58(3):773-7.
41. Hautmann AH, Schroeder J, Wild P, Hautmann MG, Huber E, Hoffstetter P, et al. Tumor-induced osteomalacia: increased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the tibia expressing periostin. Case Rep Endocrinol. 2014;2014:729387.
42. Ogura E, Kageyama K, Fukumoto S, Yagihashi N, Fukuda Y, Kikuchi T, et al. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23. Intern Med Tokyo Jpn. 2008;47(7):637-41.
43. Seufert J, Ebert K, Müller J, Eulert J, Hendrich C, Werner E, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345(26):1883-8.
44. Chong WH, Yavuz S, Patel SM, Chen CC, Collins MT. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2001;96(12):3599-600.
45. Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging. Intern Med J. 2003;33(12):615-6.
46. Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359(9308):761-3.
47. Moran M, Paul A. Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia. Int Orthop. 2002;26(1):61-2.
48. Dupond JL, Mahammedi H, Prié D, Collin F, Gil H, Blagosklonov O, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36(3):375-8.
49. Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res Off J Am Soc Bone Miner Res. 2011;26(6):1295-302.
50. Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011;17(2):177-84.
51. Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40(1):e6-10.
52. Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB, Lim SK. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf). 2001;54(4):551-4.
53. Rodrigues NR, Calich AL, Etchebehere M, Ichiki WA, Pereira FP, Amstalden EMI, et al. Whole-body (99m)Tc-octreotide scintigraphy with SPECT/CT to detect occult tumor inducing paraneoplastic osteomalacia. Clin Nucl Med. 2015;40(1):54-7.
54. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982-93.
55. Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92(6):2374-7.
56. Harvey JN, Gray C, Belchetz PE. Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf). 1992;37(4):379-82.
57. Paglia F, Dionisi S, Minisola S. Octreotide for tumor-induced osteomalacia. N Engl J Med. 2002;346(22):1748-9. author reply 1748-9.
58. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2007;22(6):931-7.
59. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;24(11):1879-88.
60. Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587-97.
61. Kinoshita Y, Fukumoto S. Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia. Clin Calcium. 2014;24(8):1217-22.